Europe’s pharma industry saw a drop of 11.1% in deal activity during March 2019, when compared with the last 12-month average, according to GlobalData’s deals database.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all
  • Embed this chart

    Embed this chart into your website

    Copy and paste the code below into your website to display the chart.

A total of 24 pharma industry deals worth $2.86bn were announced for the region in March 2019, against the 12-month average of 27 deals.

Of all the deal types, M&A saw most activity in March 2019 with 11 transactions, representing a 45.8% share for the region.

In second place was venture financing with 11 deals, followed by private equity deals with two transactions, respectively capturing a 45.8% and 8.3% share of the overall deal activity for the month.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

In terms of value of deals, M&A was the leading category in Europe’s pharma industry with $1.93bn, while private equity and venture financing deals totalled $830.01m and $107.06m, respectively.

Europe pharma industry deals in March 2019: Top deals

The top five pharma deals accounted for 96.2% of the overall value during March 2019.

The combined value of the top five pharma deals stood at $2.75bn, against the overall value of $2.86bn recorded for the month. The top announced pharma deal tracked by GlobalData in March 2019 was Fujifilm’s $890m acquisition of Biogen Denmark Manufacturing.

In second place was the $877m acquisition of Nightstar Therapeutics by Biogen and in third place was Waypoint Group Holdings’ $830.01m private equity deal with Stallergenes Greer.

The $105m asset transaction with GW Research by Biohaven Pharmaceutical Holding and Pfizer’s acquisition of Vivet Therapeutics for $51.09m held fourth and fifth positions, respectively.

This analysis considers only announced and completed deals from the GlobalData financial deals database and excludes all terminated and rumoured deals. Country and industry are defined according to the headquarters and dominant industry of the target firm. The term ‘acquisition’ refers to both completed deals and those in the bidding stage.

GlobalData tracks real-time data concerning all merger and acquisition, private equity/venture capital and asset transaction activity around the world from thousands of company websites and other reliable sources.

More in-depth reports and analysis on all reported deals are available for subscribers to GlobalData’s deals database.